Related Experiment Video
Updated: Feb 19, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.5K
CD36 Deficiency Suppresses Epileptic Seizures
Fangshuo Zheng1, Yong Yang1, Shanshan Lu1
1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, 1 Youyi Road, Chongqing 400016, China.
Neuroscience
|November 8, 2017
Summary
Cluster of differentiation 36 (CD36) is elevated in epilepsy. CD36 deficiency in mice reduced neuronal hyperexcitability and seizure susceptibility, suggesting a potential new epilepsy treatment.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Cluster of differentiation 36 (CD36) is a scavenger receptor implicated in various central nervous system (CNS) diseases.
- The specific role of CD36 in epilepsy pathogenesis is not yet understood.
Purpose of the Study:
- To investigate CD36 expression in chronic epileptic mouse models.
- To determine if CD36 deficiency impacts neuronal hyperexcitability and epilepsy susceptibility.
Main Methods:
- Utilized pentylenetetrazol (PTZ) and kainic acid (KA) induced chronic epileptic mouse models.
- Analyzed CD36 expression in neurons.
- Conducted behavioral studies on CD36-deficient (CD36-/-) and wild-type (WT) mice.
- Employed whole-cell patch-clamp and local field potential (LFP) techniques.
Main Results:
- CD36 expression was significantly elevated in epileptic mouse models.
- CD36-/- mice exhibited attenuated chronic epilepsy progression compared to WT mice.
- CD36 deficiency led to decreased action potential frequency in hippocampal neurons.
- CD36 deletion reduced the frequency and duration of epileptiform-like discharges.
Conclusions:
- CD36 deficiency demonstrates an antiepileptic effect.
- Targeting CD36 may offer a novel therapeutic strategy for epilepsy treatment.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
732
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
732
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.3K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.3K
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.8K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
962
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
962